secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000885725-24-000003
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific to acquire Axonics for $3.7B, expanding urology portfolio into sacral neuromodulation
--------------------------------------------------------------------------------

- Purchase price of $71 per share cash; equity value ~$3.7B, enterprise value ~$3.4B.
- Axonics 2023 revenue ~$366M (+34% YoY); deal expected to close H1 2024.
- Axonics offers SNM therapy for overactive bladder and fecal incontinence with Axonics R20 neurostimulator (20+ year battery).
- Deal expected to be immaterial to BSX adjusted EPS in 2024, accretive thereafter.
- Expands BSX urology portfolio into high-growth SNM adjacency, targeting ~30M OAB patients in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/0000885725-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/bsx-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer